Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651650 | 0.96 | CRBN (0.57) | DDB1CRBNGRM2IKZF3TNF | |
| SCHEMBL23979412 | 0.93 | DDB1 (0.52) | DDB1CRBNGRM2IKZF3TNF | |
| SCHEMBL3656297 | 0.89 | DDB1 (0.57) | DDB1CRBNGRM2IKZF3TNF | |
| SCHEMBL4102412 | 0.84 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12638497 | 0.83 | DDB1 (0.47) | DDB1CRBNGRM2IKZF3TNF | |
| SCHEMBL23979400 | 0.81 | CRBN (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23980066 | 0.80 | DDB1 (0.54) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23979588 | 0.80 | DDB1 (0.53) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16221493 | 0.80 | CRBN (0.52) | DDB1CRBNGRM2IKZF3BRD4 | |
| SCHEMBL21751060 | 0.80 | CRBN (0.55) | DDB1CRBNGRM2IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SALARIUS PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | HPGDS, HPGD, AQP3 | DDB1 690/4885CRBN 1079/4885GRM2 4210/4885 |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | HPGDS, HPGD, AQP3 | DDB1 690/4885CRBN 1079/4885GRM2 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.